KR20220002427A - 항-rsv 항체를 포함하는 조성물 및 이의 투여 요법 - Google Patents

항-rsv 항체를 포함하는 조성물 및 이의 투여 요법 Download PDF

Info

Publication number
KR20220002427A
KR20220002427A KR1020217038129A KR20217038129A KR20220002427A KR 20220002427 A KR20220002427 A KR 20220002427A KR 1020217038129 A KR1020217038129 A KR 1020217038129A KR 20217038129 A KR20217038129 A KR 20217038129A KR 20220002427 A KR20220002427 A KR 20220002427A
Authority
KR
South Korea
Prior art keywords
rsv
patient
antigen
binding fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217038129A
Other languages
English (en)
Korean (ko)
Inventor
아니스 아메드 칸
바드린 피에르
Original Assignee
메디뮨 리미티드
사노피 파스퇴르 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 사노피 파스퇴르 인크 filed Critical 메디뮨 리미티드
Publication of KR20220002427A publication Critical patent/KR20220002427A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C07K16/1027—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
KR1020217038129A 2019-04-30 2020-04-30 항-rsv 항체를 포함하는 조성물 및 이의 투여 요법 Pending KR20220002427A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
KR20220002427A true KR20220002427A (ko) 2022-01-06

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038129A Pending KR20220002427A (ko) 2019-04-30 2020-04-30 항-rsv 항체를 포함하는 조성물 및 이의 투여 요법

Country Status (15)

Country Link
US (3) US12024553B2 (https=)
EP (1) EP3962940A1 (https=)
JP (2) JP2022531205A (https=)
KR (1) KR20220002427A (https=)
CN (1) CN113825767A (https=)
AU (1) AU2020265676A1 (https=)
BR (1) BR112021020846A2 (https=)
CA (1) CA3138180A1 (https=)
CO (1) CO2021014370A2 (https=)
EA (1) EA202192776A1 (https=)
IL (1) IL287443A (https=)
MX (1) MX2021013248A (https=)
SG (1) SG11202111748TA (https=)
TW (1) TWI861099B (https=)
WO (1) WO2020223435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2023039584A2 (en) * 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Also Published As

Publication number Publication date
EA202192776A1 (ru) 2022-01-19
JP2025072444A (ja) 2025-05-09
TWI861099B (zh) 2024-11-11
US20220204593A1 (en) 2022-06-30
JP2022531205A (ja) 2022-07-06
CN113825767A (zh) 2021-12-21
WO2020223435A1 (en) 2020-11-05
TW202106333A (zh) 2021-02-16
CA3138180A1 (en) 2020-11-05
AU2020265676A1 (en) 2021-11-18
SG11202111748TA (en) 2021-11-29
BR112021020846A2 (pt) 2022-01-18
US20240417447A1 (en) 2024-12-19
US20200347120A1 (en) 2020-11-05
CO2021014370A2 (es) 2021-10-29
EP3962940A1 (en) 2022-03-09
MX2021013248A (es) 2022-01-24
IL287443A (en) 2021-12-01
US12024553B2 (en) 2024-07-02

Similar Documents

Publication Publication Date Title
US11339206B2 (en) Compositions and methods for the treatment of immunodeficiency
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
TW202200610A (zh) 針對嚴重急性呼吸症候群冠狀病毒２（ＳＡＲＳ—ＣｏＶ—２）之人單株抗體
BR112013011176A2 (pt) métodos de tratamento de artrite reumatoide usando antagonistas de il-17
US20240417447A1 (en) Dosage regimens for and compositions including anti-rsv antibodies
JP2025515237A (ja) Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
CN110891968B (zh) 生物制药组合物和相关方法
US20210277093A1 (en) Immunotherapeutic compositions and methods of production for coronavirus
CN114644708A (zh) 呼吸道合胞病毒特异性结合分子
AU2022361501B2 (en) Anti-sars-cov-2 antibodies and uses thereof i
US20240400653A1 (en) Anti-sars-cov-2 antibodies and uses thereof i
US20260092100A1 (en) Antibodies against metapneumovirus fusion (f) protein and uses thereof
EA046902B1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
US20250188153A1 (en) Hmpv antibodies and their use
Naismith et al. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2
WO2022079001A2 (en) Sars-cov-2 antigens, diagnostic and therapeutic uses
WO2025217677A1 (en) Methods for treating neutrophilic skin conditions
JP2024535009A (ja) ニルセビマブによる呼吸器合胞体ウイルス下気道感染の予防

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000